Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 16/20 | 0.60 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.47 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.47 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.46 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.46 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.45 |
| ▸ | CDK2 | P24941 | 1/20 | 0.45 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1261510 | 0.86 | GCK (0.62) | GCKCSNK2A2CSNK2A1CCNE1CDK2 | |
| SCHEMBL2659733 | 0.85 | GCK (0.52) | GCKCSNK2A2CSNK2A1 | |
| SCHEMBL2659735 | 0.85 | GCK (0.52) | GCKCSNK2A2CSNK2A1 | |
| SCHEMBL2666419 | 0.83 | CSNK2A2 (0.44) | GCKCSNK2A2CSNK2A1CSNK2BCSNK2A3 | |
| SCHEMBL2660394 | 0.82 | GCK (0.57) | GCKCSNK2A2CSNK2A1 | |
| SCHEMBL1261642 | 0.81 | GCK (0.56) | GCKCSNK2A2CSNK2A1CCNE1CDK2 | |
| SCHEMBL1261323 | 0.80 | GCK (0.55) | GCKCSNK2A2CSNK2A1 | |
| SCHEMBL1262312 | 0.79 | GCK (0.55) | GCKCSNK2A2CSNK2A1CCNE1CDK2 | |
| SCHEMBL1262938 | 0.79 | GCK (0.55) | GCKCSNK2A2CSNK2A1CCNE1CDK2 | |
| SCHEMBL1262625 | 0.79 | GCK (0.54) | GCKCSNK2A2CSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8211925-B2 | Benzamide glucokinase activators | TRANSTECH PHARMA, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-20100331379-A1 | BENZAMIDE GLUCOKINASE ACTIVATORS | VTVX HOLDINGS I LLC | 2010-12-30 | — | — | US | disclosed |
| EP-2019823-B1 | BENZAMIDE GLUCOKINASE ACTIVATORS | TRANSTECH PHARMA INC (US) | 2010-11-24 | — | — | EP | disclosed |
| EP-2019823-A2 | BENZAMIDE GLUCOKINASE ACTIVATORS | Transtech Pharma, Inc. (US) | 2009-02-04 | — | — | EP | disclosed |
| WO-2007125105-A2 | BENZAMIDE GLUCOKINASE ACTIVATORS | TRANSTECH PHARMA, INC. (US) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331379-A1 | BENZAMIDE GLUCOKINASE ACTIVATORS | GCK, GCKR, HK2 | GCK 1/4885CSNK2A2 1011/4885CSNK2A1 1224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.